Awards 2023. 04. 18

Innorna was listed on the 2023 “PEdaily Top 100 Sci-Tech Innovation Companies”

Recently, the "China Sci-Tech Innovation Investment Summit" co-sponsored by Zero2IPO and PEdaily was held in Yangzhou. During the summit, PEdaily officially released the list of the 2023 “PEdaily Top 100 Sci-Tech Innovation Companies”.


The “PEdaily Top 100 Sci-Tech Innovation Companies” list is dedicated to identifying private technology innovation companies. It selects companies from multiple dimensions such as technological innovation, business model, competition barriers, and future business value. 100 technological innovation companies that represent the future direction of the industries were selected among the high-tech industries and strategic emerging industries such as new materials, new energy, energy conservation and environmental protection, and biomedicine, as well as the scientific and technological innovation groups deeply integrated with the Internet, big data, cloud computing, artificial intelligence and manufacturing. 


With its LNP technology platform with international independent intellectual property rights, Innorna was selected as one of 19 companies from the medical and biological sector for this list. Innorna has the underlying innovation capabilities of the LNP delivery system and its proprietary LNP technology platform can design and build tens of thousands of ionizable phospholipid libraries. It can screen out the best LNP carriers for different treatment scenarios and has great application potential for the fields such as mRNA, small nucleic acid, gene editing and etc. Because of these capabilities, Innorna is favored by many large domestic and foreign pharmaceutical companies and have developed partnership with them. 


Thanks to Zero2IPO, PEdaily and industry experts for their recognition of Innorna. Innorna will continue to uphold the spirit of scientific innovation and is committed to accelerating the development and application of new drugs and vaccines through the innovation of drug delivery systems. It will strive to contribute to the development of the biomedical industry and serving the unmet clinical needs!